Spontaneous Urticaria
📧 Sign up to get email alerts when something new happens for Spontaneous Urticaria.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria [Phase 3]
Phase 3 trial comparing CT-P39 to EU-approved Xolair (omalizumab) in chronic spontaneous urticaria; results have been completed and posted.
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany
This clinical trial update describes a study comparing digital disease monitoring with in-person visits for Chronic Spontaneous Urticaria in…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria [Phase 1]
A Phase 1 study update reports completion of evaluating AK006 for safety, tolerability, pharmacokinetics, and immunogenicity in healthy part…
-
CLINICAL_TRIALS trial_result · 2025-04-30Clinical Trial Update: A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. [Phase 3]
A multicenter Phase 3 open-label trial evaluating remibrutinib added to H1-antihistamines for adults with chronic spontaneous urticaria inad…
-
CLINICAL_TRIALS research · 2025-04-11Clinical Trial Update: Interleukin-2 for Refractory Chronic Spontaneous Urticaria [Phase 2, Phase 3]
Clinical trial update indicates a Phase 2/3 study of interleukin-2 for refractory chronic spontaneous urticaria is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria [Phase 2]
This document reports the completion of a Phase 2 trial evaluating CDX-0159 in patients with chronic spontaneous urticaria. The study status…
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria. [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of HS-10561 capsules in h…
-
CLINICAL_TRIALS research · 2024-12-27Clinical Trial Update: A Study of Efficacy and Safety of TLL-018 in CSU Participants [Phase 3]
Phase 3 clinical trial update for TLL-018 in chronic spontaneous urticaria, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-12-02Clinical Trial Update: A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines [Phase 3]
This update reports the completion of a Phase 3 trial evaluating the efficacy and safety of remibrutinib in adults with chronic spontaneous …
-
CLINICAL_TRIALS research · 2024-11-29Clinical Trial Update: Trial of JYB1904 in Chronic Spontaneous Urticaria. [Phase 2]
A Phase 2 clinical trial evaluating JYB1904 for chronic spontaneous urticaria is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines [Phase 3]
A Phase 3 trial evaluating the safety and efficacy of remibrutinib in Japanese adults with chronic spontaneous urticaria inadequately contro…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases [Phase 1]
A single-dose, Phase 1 study of YH35324 in patients with allergic diseases, including chronic spontaneous urticaria and chronic inducible ur…
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines [Phase 3]
A Phase 3 trial evaluating the efficacy and safety of remibrutinib in adults with chronic spontaneous urticaria inadequately controlled by H…
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria [Phase 2]
A Phase 2 trial of subcutaneous lirentelimab (AK002) in chronic spontaneous urticaria was terminated, with results posted on 2024-09-27.
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria [Phase 2]
This document reports the completion of a Phase 2a trial evaluating TAS5315 in patients with chronic spontaneous urticaria. No efficacy or s…
-
CLINICAL_TRIALS trial_result · 2024-07-19Clinical Trial Update: Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine [Phase 2]
A Phase 2 clinical trial evaluating rilzabrutinib for chronic spontaneous urticaria in patients with persistent symptoms despite H1 antihist…
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria [Phase 1]
A Phase 1 study evaluating the mechanism of action of Ligelizumab (QGE031) in patients with chronic urticaria has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria [Phase 2]
Amgen's Phase 2 study evaluating tezepelumab in adults with chronic spontaneous urticaria has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients [Phase 2]
Phase 2 trial evaluating cannabidiol (CBD) as a steroid-sparing therapy for chronic spontaneous urticaria has completed.
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. [Phase 3]
This document reports the completion and posting of Phase III results for ligelizumab in adolescents and adults with chronic spontaneous urt…
-
CLINICAL_TRIALS trial_result · 2024-03-13Clinical Trial Update: A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) [Phase 2]
Phase 2 clinical trial of benralizumab in chronic spontaneous urticaria terminated; results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines [Phase 3]
Phase 3 safety and efficacy results for ligelizumab in chronic spontaneous urticaria in Japanese patients inadequately controlled with H1 an…
-
CLINICAL_TRIALS trial_result · 2024-03-07Clinical Trial Update: A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria [Phase 2]
Phase 2 clinical trial investigating the efficacy and safety of HWH486 in adults with chronic spontaneous urticaria.
-
CLINICAL_TRIALS trial_result · 2024-02-09Clinical Trial Update: Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU) [Phase 4]
Phase 4 trial update on histamine human immunoglobulin for chronic spontaneous urticaria evaluating efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2023-09-29Clinical Trial Update: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU [Phase 2]
An open-label extension of Phase 2 evaluating the long-term safety and tolerability of the investigational agent LOU064 in adults with chron…